Article Text
Statistics from Altmetric.com
QUESTION: In adults with lateral epicondylitis (tennis elbow), which of 3 regimens (local corticosteroid injection, 2 weeks of naproxen, or simple analgesia) is most effective?
Design
Randomised {allocation concealed*}†, blinded (outcome assessor and statistician),* placebo controlled trial with 12 months follow up.
Setting
23 primary care practices in North Staffordshire and South Cheshire, England.
Patients
164 patients who were 18–70 years of age (66% ≥45 y, 52% men) and had consulted their general practitioner because they had had a new episode of lateral epicondylitis. Exclusion criteria were a history of inflam-matory arthritis or gross structural abnormality of the elbow, contraindications to non-steroidal anti-inflammatory drugs (NSAIDs) or local steroid injection, pregnancy, or breast feeding. 98% of patients were included in the analysis for 4 week complete recovery, 96% for 4 week and 12 month pain severity, and 98% for 6 month pain severity.
Intervention
Patients were allocated to a local corticosteroid injection of methylprednisolone, 20 mg, and 1% lignocaine, 0.5 ml (n=53); enteric coated naproxen, 500 mg twice daily for 2 weeks (n=53); or placebo for 2 weeks (n=58). Patients received co-codamol (a combination of paracetamol [acetaminophen] and codeine, 8 mg) for additional pain relief.
Main outcome measure
Patients' global assessment of change (5 point scale). Secondary outcomes included pain severity (10 point Likert scale).
Main results
Analysis was by intention to treat. More patients in the injection group than in the naproxen or placebo groups reported complete recovery and had pain scores ≤3 at 4 weeks (p<0.05 for all comparisons) (table). At 6 months, fewer patients in the injection group than in the placebo group had pain scores ≤3 (p<0.05) (table). At 12 months, ≥80% of patients in each group had pain scores ≤3.
Local corticosteroid injection (inj), naproxen (nap), and placebo (pl) for lateral epicondylitis‡
Conclusions
In patients with acute lateral epicondylitis, local corticosteroid injection was most effective for relieving symptoms at 4 weeks but not at 6 months. At 1 year, local injection, naproxen, and simple analgesia led to similar rates of symptom relief.
Commentary
This pragmatic randomised controlled trial by Hay et al, in which primary care patients were followed up for 1 year, overcomes many of the limitations of previous trials,1 and allows some realistic clinical conclusions to be drawn.
This study confirms that a local injection of methylprednisolone, 20 mg, and lignocaine is effective in the treatment of lateral epicondylitis, providing short term relief from pain. However, some patients who respond well to injection will probably relapse by 6 months.
On the other hand, NSAID treatment, in the form of naproxen, 500 mg twice daily for 2 weeks, fared no better than placebo at any point during follow up. Some 30% of patients randomly allocated to the naproxen and placebo treatment groups received a corticosteroid injection during the follow up period. In view of the lack of evidence that 1 form of NSAID performs any better than another or that NSAIDs are more effective than simple analgesics, NSAIDs apparently have no role in treating tennis elbow.2
No matter what treatment was given—local injection, NSAID, or placebo—the outcome at 1 year was similar, with almost all patients making a satisfactory recovery. The remaining question is: what role, if any, does physical therapy have in the treatment of lateral epicondylitis?
Footnotes
-
Sources of funding: Arthritis Research Campaign. UpJohn provided methylprednisolone injections; Syntex provided enteric coated naproxen.
-
For correspondence: Dr E M Hay, Staffordshire Rheumatology Centre, The Haywood, Burslem, Stoke-on-Trent ST6 7AG, UK. Fax +44 (0)1782 412236.
↵† Information provided by author.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.